Royalty Report: Disease, cardiac, Drugs – Collection: 282874

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Disease
  • cardiac
  • Drugs
  • Medical
  • Device
  • Drug Discovery
  • Biotechnology
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282874

License Grant
Licensor hereby grants Licensee a non-exclusive license under (i) Licensor Collaboration Program Inventions and Results, (ii) Licensor Collaboration Program Patents, and (iii) Licensor Independent Inventions and Improvements, for the sole purposes of enabling Licensee to conduct the Collaboration Program activities assigned to Licensee or its Affiliates under the Work Plan. The foregoing license may be sublicensed to Licensee Affiliates and to Third Parties acting on behalf of Licensee.

Licensor hereby grants Licensee and itsAffiliates, during the Collaboration Program Term, an exclusive right to access, test, profile, analyze and use all Biological Samples and Data within the TALON Registry as Licensee deems scientifically appropriate. Following the Collaboration Program Term, Licensees exclusive access rights to such Biological Samples and Data shall continue when and if it Triggers the Product Exclusivity License or the Test Exclusivity License. If Licensee does not Trigger either a Product Exclusivity License or Test Exclusivity License, Licensees exclusive access rights to such Biological Samples and Data convert into non-exclusive access rights.

Licensor hereby grants to Licensee a non-exclusive, sublicensable license in the Territory under Licensor Collaboration Program Patents, and to use Licensor Collaboration Program Inventions and Results:

(i) In the Test Field, subject to the non-exclusivity milestones and royalties described; and

(ii) For all uses outside of the Test Field, subject to the non-exclusivity milestones and royalties described.

The exclusive license grants (b) shall become effective and the non-exclusive license grants (a) shall expire as follows:

(i) The exclusive license grant (b)(i) shall become effective and the non-exclusive license grant (a)(i) shall expire, immediately upon Licensee’s written notice to Licensor of its desire to trigger the Test Exclusivity License, subject to Licensee’s payment of the fee described, provided that Licensee sends such notice to Licensor prior to the expiration of the Option Period;

(ii) The exclusive license grant (b)(ii) shall become effective and the non-exclusive license grant (a)(ii) shall expire, immediately upon Licensee’s written notice to Licensor of its desire to trigger the Product Exclusivity License, subject to Licensee’s payment of the fee described in Section 5.7.1, provided that Licensee sends such notice to Licensor prior to the expiration of the Option Period.

If the making, having made, use, offer for sale, sale or import by Licensee, its Affiliates and sublicensees of Therapeutic Products or Tests would infringe during the term of this Agreement a claim of issued letters patent either in existence as of the Effective Date, or claiming priority to an application in existence as of the Effective Date and Controlled by Licensor and which patents are not otherwise covered by the license grant, Licensor hereby grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, royalty-free license in the Territory under such issued letters patent for Licensee, to develop, make, have made, use, sell, offer for sale or import Therapeutic Products, Products and Tests in the Territory. Such non-exclusive license is sublicensable, but only to the extent the sublicensee is acting on behalf of Licensee or a Licensee Affiliate.

License Property
Licensor develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery diseases, and owns and maintains the TALON Registry (as further defined below). Licensee discovers, develops and markets vaccines and medicines.  

TALON Registry means: (a) Licensor’s multi-center registry designed to capture and archive patient outcomes data, as well as all biological material, such as excised plaque using Licensor technology, which such registry is expected to be closed prior to or shortly after the Effective Date, and (b) any and all de-identified patient-related clinical and demographic data corresponding to such biological material, as well as any genetic, and genomic data associated with such collections.

Combination Product means a product containing both a Therapeutic Product as well as one or more active ingredients that are other than a Profiled Compound. All references to Product in this Agreement shall be deemed to include Combination Products.

Product means each of the Dose Ranging Product, Labeled Product and Enhanced Labeled Product, and each Products means all such products, collectively. Product also includes any Combination Product

Therapeutic Product means any pharmaceutical or biological preparation in final form containing a Profiled Compound for: (a) sale by prescription, over-the-counter or any other method; or (b) administration to human patients in a Phase III Clinical Trial.

Profiled Compound means any chemical compound (including but not limited to small molecules, proteins, antibodies and therapeutic nucleic acids): (a) for which Biological Samples and Data is generated concerning such compound’s effectiveness; or (b) the discovery, identification or development of which utilizes or is based upon Collaboration Program Inventions and Results.

Collaboration Program Patent Rights means any and all patents and patent applications (which for the purposes of this Agreement shall be deemed to include certificates of invention, provisional applications, and applications for certificates of invention) claiming any Collaboration Program Invention and Results.

Field of Use
Test Field means the development, use and commercialization of Tests.  'Test' means (a) a prognostic test [aimed at predicting the response or non-response to a compound] and/or (b) a diagnostic test [aimed at determining (i) susceptibility to, or severity or presence of, a particular disease or condition in humans and/or animals]; and/or (ii) [response to a therapy].

The Parties agreed to collaborate on the analysis of atherosclerotic plaque removed from patient arteries with the goal of identifying new biomarkers of atherosclerotic disease progression.

Atherosclerosis is a disease in which plaque builds up inside your arteries. Arteries are blood vessels that carry oxygen-rich blood to your heart and other parts of your body. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Over time, plaque hardens and narrows your arteries.

IPSCIO Record ID: 280326

License Grant
The parties wish to enter into a collaboration employing Licensees medicinal chemistry, analytical chemistry and primary biology capabilities and Licensors chemistry, in vitro biology, and in vivo biology capabilities, in order to develop and commercialize pharmaceutical compounds subject to and in accordance with the terms and conditions of this Agreement (the “Collaboration”).

License to Commercialize Collaboration Compounds – With respect to all Collaboration Compounds for which Licensee has received Licensors approval to develop and commercialize, Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensor’s interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License to Compounds (Other than Collaboration Compounds) Derived from Licensee Compounds –  Licensor grants to Licensee a worldwide, perpetual, exclusive, royalty-free license, with the right to sublicense, under Licensors interest in the Collaboration IP, to exploit for any and all purposes all compounds (other than Collaboration Compounds) derived, directly or indirectly, from Licensee Compounds.

Research Licenses – The Parties hereby grant each other non-exclusive, worldwide, royalty-free research licenses, without the right to sublicense, under their respective interests in the Licensee IP, Licensor IP and Collaboration IP, in order for each Party to perform its research obligations pursuant to Research Plans during the Collaboration Term.

License Property
Collaboration Product shall mean a pharmaceutical product containing a Collaboration Compound that is sold by Licensor or Licensee, or their respective Sublicensees or Affiliates.  It is understood that, in the event any Collaboration Compound is sold for therapeutic purposes, such Collaboration Compound shall be deemed a Collaboration Product and shall be subject to milestones and royalties as set forth in this Agreement.

Collaboration Compound shall mean a Licensee Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensor Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC.  A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensee or Licensor or their Affiliates to protect any compound in category (i), (ii) or (iii) above.  A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above.  For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensor Compound, Licensee Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.

Joint Research Committee or “JRC” shall mean the entity organized to manage the scientific implementation of the Collaboration.

Licensor IP shall mean Licensor Patents and Licensor Know-how.

Collaboration IP shall mean Collaboration Patents and Collaboration Know-how.  Collaboration IP shall not include Licensee IP or Licensor IP.

Licensee IP shall mean Licensee Patents and Licensee Know-how.  Licensee IP shall not include any intellectual property owned or licensed by Licensee or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).

Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the effective date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the Effective Date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensor, Licensee or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensee or Licensor during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensor Patents or Licensee Patents.

Licensee Compound shall mean any compound brought to the Collaboration by Licensee, which is Controlled by Licensee at or after the Effective Date, and which is proprietary to Licensee by virtue of being within the Licensee IP.

Field of Use
Licensee Field shall mean, with respect to each Collaboration Compound for which Licensee has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

Licensor Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.

IPSCIO Record ID: 280977

License Grant
Licensor grants a worldwide, nonexclusive, license to use and practice Licensor Background Technology solely to the extent necessary to for Licensee to perform its obligations under the Research Program.

For abandoned compounds, Licensor grants a license, for use solely within the field , under any patent rights owned or controlled by Licensor relating to the composition or use or manufacture of any such abandoned Collaboration Compound or Product owned or controlled by Licensor or that was licensed by Licensee to Licensor, and to any regulatory filings, Pre-Clinical Data, and Clinical Data owned or controlled by Licensor relating to any such Collaboration Compound or Product for development or use within the Field.   Such license shall be exclusive as to the commercialization of any Collaboration Compound or Product for use within the field and shall be non-exclusive for any other use or purpose within the field, such as use of collaboration compounds for research and development purposes.

License Property
Licensor has certain expertise in the discovery, development, marketing and sales of pharmaceutical products.

The license is for Formulae for Licensees Mineralocorticoid Antagonist Leads.

The collaboration tagreement focuses on the discovery, design, and development of orally active compounds that selectively modulate the mineralocorticoid receptor.

Field of Use
Field shall mean the discovery, characterization, design, development and commercialization of small molecule compounds for the treatment or prevention of diseases whose therapeutic, prophylactic or other beneficial effects are mediated, in whole or in material part, through direct modulation of the Designated Target.

This receptor plays a critical role in many illnesses, particularly cardiovascular diseases such as congestive heart failure and hypertension.

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.